QuidelOrtho shared its Q3 results, showing $619 million in sales, which is down 12% from last year.

Nov 3, 2026, 5:44 PM ETResultsRead the original at Benzinga

Bad for QDEL

QuidelOrtho's sales fell 12%, with China down 45% and point-of-care down 27%. Core growth and planned yearly savings above $80 million help, but ongoing China pressure and weak respiratory demand weigh more.

QDEL · QuidelOrtho

AI read · Bad for QDEL

The AI's read

China's pricing rules are prompting customers to cut orders, and weaker respiratory testing is hurting point-of-care sales. Management expects China pressure to continue into 2027. Outside China, labs and blood testing grew, and the savings plan could help profit and cash. Those gains do not outweigh the declines in China and respiratory testing.

Get alerts for QDEL

Follow QuidelOrtho (QDEL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for QDEL

Free on the App Store and Google Play, or on the web.